Haemophilia prophylactic licensed
A prophylactic agent has been granted a license for haemophilia A patients with inhibitors.
Factor VIII Inhibitor Bypassing Activity (FEIBA) reduces a patient’s risk of spontaneous bleeds, minimising long-term complications, according to manufacturer Baxter. It is the first bypassing agent to be granted a prophylaxis indication for this group of patients.
Kate Khair, nurse consultant in haemophilia at Great Ormond Street Hospital in London, said: ‘Treating patients with inhibitors with FEIBA prophylaxis has a profound effect on the everyday life of a patient.’